Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. PEG-interferon alfa-2a may interfere with the growth of tumor cells
and slow the growth of skin cancer. Giving gefitinib together with PEG-interferon alfa-2a may
kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of PEG-interferon
alfa-2a when given together with gefitinib and to see how well they work in treating patients
with unresectable or metastatic skin cancer.